EUCTR2014-002209-39-NL进行中（未招募）1 期
Phase I/II study with lapatinib plus trametinib in patients with metastaticKRAS mutant non-small cell lungcancer - Lapatinib plus trametinib in KRASm non-small cell lung cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histological or cytological proof of metastatic NSCLC ; for PART B: treated with first line therapy for metastatic disease only.
- •2.Written documentation of a known pathogenic KRAS (exon 2, 3 or 4) mutation and PIK3CA wild-type (exon 9 and 20).
- •3.Age = 18 years.
- •4.Able and willing to give written informed consent.
- •5.WHO performance status of 0 or 1 (part A and B)
- •6.Able to swallow and retain orally administered medications and does not have clinically significant gastrointestinal abnormalities that may alter absorption (e.g. malabsorption syndrome or major resection of the stomach or bowel)
- •7.Able and willing to undergo blood sampling for PK and PD analysis.
- •8.Able and willing to undergo a tumor biopsy prior to start, after two weeks on therapy and upon progression of disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 32
排除标准
- •1.Any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment.
- •2.History of another primary malignancy
- •3.Symptomatic or untreated leptomeningeal disease.
- •4.Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy (for at least 6 weeks) are allowed to enrol. Radiotherapy for brain metastasis must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive anti-epileptic drugs or corticosteroids.
- •5.Patients previously treated with any targeted drug combination known to interfere with EGFR, HER-2, HER-3, HER-4 or MAPK- and PI3K-pathway components, including inhibitors of PI3K, AKT, mTOR, BRAF, MEK and ERK.
- •6.History of interstitial lung disease or pneumonitis
研究者
相似试验
已完成
不适用
Phase I/II study with lapatinib plus trametinib in patients with metastatic KRAS mutant non-small cell lung cancer10038666non-small cell lung cancerNL-OMON46994Antoni van Leeuwenhoek Ziekenhuis132
进行中（未招募）
不适用
Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpressioPatients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breastMedDRA version: 14.1Level: LLTClassification code 10006174Term: Breast adenocarcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065348Term: Breast adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2008-000528-22-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
已完成
2 期
Phase II study of lapatinib plus capecitabin for the HER2 overexpressing metastatic breast cancer patients pretreated with oral-FU agents.Breast cancerJPRN-UMIN000002456Saitama Breast Cancer Clinical Study Group(SBCCSG)30
招募中
2 期
A Phase II Trial of Lapatinib and Trastuzumab in Patients with Heavily Pretreated Metastatic Breast CancerHER2 positive breast cancer patients treted with multiple cytotoxic agent including trastuzumabJPRN-UMIN000002651ational Cancer Center Hospital25
撤回
2 期
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast CancerBreast NeoplasmsNCT01557764Washington University School of Medicine